The collaboration could help solve challenges for both businesses.
These stocks, a bargain today, are players to hold on to for the long term.
They might not be profitable yet, but they're swinging for the fences.
These stocks could rocket higher, but they also present significant risks.
There's a lot to like about this business, but it's still a risky bet.
There are some great companies at attractive prices in the lucrative pharmaceutical space.
It isn't ready for membership today, but it could have a path in the future.
There wasn't much to like in Ginkgo's Q4 update.
Ginkgo Bioworks says it is experiencing strong growth from its biopharma customers.
These two businesses have viable paths to making investors richer -- possibly soon.